Veracyte, Inc.
VCYT
Rangering i aksjer
#4359
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aksjekurs
$44.93
Sist synkronisert: 2026-10-20
Markedsverdi
$3.61B
Endring (1 dag)
2.57%
Endring (1 år)
24.45%
Land
US
Handel Veracyte, Inc. (VCYT)
Kategori
Healthcare
P/S-forhold for Veracyte, Inc. (VCYT)
P/S-forhold per October 2026 TTM: 6.22
Ifølge Veracyte, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 6.22. Ved slutten av 2023 hadde selskapet et P/S-forhold på 5.54.
P/S-historikk for Veracyte, Inc. fra 2011 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.22 | -8.32% |
| 2024 | 6.79 | 22.75% |
| 2023 | 5.54 | -3.33% |
| 2022 | 5.73 | -55.07% |
| 2021 | 12.74 | -42.55% |
| 2020 | 22.18 | 107.23% |
| 2019 | 10.70 | 111.43% |
| 2018 | 5.06 | 64.40% |
| 2017 | 3.08 | -10.20% |
| 2016 | 3.43 | -9.14% |
| 2015 | 3.77 | -31.06% |
| 2014 | 5.47 | 98.64% |
| 2013 | 2.76 | -82.96% |
| 2012 | 16.18 | -77.25% |
| 2011 | 71.11 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 5.37 | -13.70% |
US
|
|
| 6.29 | 1.08% |
US
|
|
| 21.02 | 237.66% |
US
|
|
| - | - |
CN
|
|
| 6.67 | 7.09% |
US
|
